These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19282778)

  • 1. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.
    Brothers CH; Hernandez JE; Cutrell AG; Curtis L; Ait-Khaled M; Bowlin SJ; Hughes SH; Yeo JM; Lapierre DH
    J Acquir Immune Defic Syndr; 2009 May; 51(1):20-8. PubMed ID: 19282778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis.
    Ding X; Andraca-Carrera E; Cooper C; Miele P; Kornegay C; Soukup M; Marcus KA
    J Acquir Immune Defic Syndr; 2012 Dec; 61(4):441-7. PubMed ID: 22932321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abacavir use and risk of recurrent myocardial infarction.
    Sabin CA; Ryom L; d'Arminio Monforte A; Hatleberg CI; Pradier C; El-Sadr W; Kirk O; Weber R; Phillips AN; Mocroft A; Bonnet F; Law M; de Wit S; Reiss P; Lundgren JD;
    AIDS; 2018 Jan; 32(1):79-88. PubMed ID: 29028664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
    Obel N; Farkas DK; Kronborg G; Larsen CS; Pedersen G; Riis A; Pedersen C; Gerstoft J; Sørensen HT
    HIV Med; 2010 Feb; 11(2):130-6. PubMed ID: 19682101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.
    Worm SW; Sabin C; Weber R; Reiss P; El-Sadr W; Dabis F; De Wit S; Law M; Monforte AD; Friis-Møller N; Kirk O; Fontas E; Weller I; Phillips A; Lundgren J
    J Infect Dis; 2010 Feb; 201(3):318-30. PubMed ID: 20039804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.
    Cruciani M; Zanichelli V; Serpelloni G; Bosco O; Malena M; Mazzi R; Mengoli C; Parisi SG; Moyle G
    AIDS; 2011 Oct; 25(16):1993-2004. PubMed ID: 21716077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.
    Ribaudo HJ; Benson CA; Zheng Y; Koletar SL; Collier AC; Lok JJ; Smurzynski M; Bosch RJ; Bastow B; Schouten JT;
    Clin Infect Dis; 2011 Apr; 52(7):929-40. PubMed ID: 21427402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of myocardial infarction and coronary artery disease in subjects taking lopinavir/ritonavir: a study using clinical trial and pharmacovigilance databases.
    Da Silva B; Tschampa J; Beron J; Fredrick L; Patwardhan M; Zachry W; Woodward WC; Norton M; Nilius A
    Int J Clin Pharmacol Ther; 2012 Jun; 50(6):391-402. PubMed ID: 22541744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV.
    Elion RA; Althoff KN; Zhang J; Moore RD; Gange SJ; Kitahata MM; Crane HM; Drozd DR; Stein JH; Klein MB; Eron JJ; Silverberg MJ; Mathews WC; Justice AC; Sterling TR; Rabkin CS; Mayor AM; Klein DB; Horberg MA; Bosch RJ; Eyawo O; Palella FJ;
    J Acquir Immune Defic Syndr; 2018 May; 78(1):62-72. PubMed ID: 29419568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.
    Sabin CA; Reiss P; Ryom L; Phillips AN; Weber R; Law M; Fontas E; Mocroft A; de Wit S; Smith C; Dabis F; d'Arminio Monforte A; El-Sadr W; Lundgren JD;
    BMC Med; 2016 Mar; 14():61. PubMed ID: 27036962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
    Lang S; Mary-Krause M; Cotte L; Gilquin J; Partisani M; Simon A; Boccara F; Costagliola D;
    Arch Intern Med; 2010 Jul; 170(14):1228-38. PubMed ID: 20660842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study.
    Dorjee K; Baxi SM; Reingold AL; Hubbard A
    BMC Infect Dis; 2017 Oct; 17(1):708. PubMed ID: 29078761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abacavir and cardiovascular disease: A critical look at the data.
    Llibre JM; Hill A
    Antiviral Res; 2016 Aug; 132():116-21. PubMed ID: 27260856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials.
    Nan C; Shaefer M; Urbaityte R; Oyee J; Hopking J; Ragone L; Perger T; Win B; Vangerow H; McCoig C; Vannappagari V
    Open Forum Infect Dis; 2018 May; 5(5):ofy086. PubMed ID: 29766019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing and Refining Myocardial Infarction Risk Estimation Among Patients With Human Immunodeficiency Virus: A Study by the Centers for AIDS Research Network of Integrated Clinical Systems.
    Feinstein MJ; Nance RM; Drozd DR; Ning H; Delaney JA; Heckbert SR; Budoff MJ; Mathews WC; Kitahata MM; Saag MS; Eron JJ; Moore RD; Achenbach CJ; Lloyd-Jones DM; Crane HM
    JAMA Cardiol; 2017 Feb; 2(2):155-162. PubMed ID: 28002550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abacavir and cardiovascular risk.
    Behrens GM; Reiss P
    Curr Opin Infect Dis; 2010 Feb; 23(1):9-14. PubMed ID: 19996748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.
    Stainsby CM; Perger TM; Vannappagari V; Mounzer KC; Hsu RK; Henegar CE; Oyee J; Urbaityte R; Lane CE; Carter LM; Pakes GE; Shaefer MS
    Pharmacotherapy; 2019 Jan; 39(1):40-54. PubMed ID: 30414209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort.
    Roen A; Laut K; Pelchen-Matthews A; Borodulina E; Caldeira L; Clarke A; Clotet B; d'Arminio Monforte A; Fätkenheuer G; Gatell Artigas JM; Karpov I; Kuznetsova A; Kyselyova G; Mozer-Lisewska I; Mulcahy F; Ragone L; Scherrer A; Uzdaviniene V; Vandekerckhove L; Vannappagari V; Ostergaard L; Mocroft A;
    HIV Med; 2018 Apr; 19(4):252-260. PubMed ID: 29271606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.
    Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Ait-Khaled M; Purdon S
    AIDS; 2000 May; 14(7):781-9. PubMed ID: 10839585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.